Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Availability of cheap HIV-AIDS drugs threatened by Indian patent law

A controversial Indian patents bill could threaten the lives of millions of people worldwide living with HIV-AIDS and cancer by banning companies from producing cheap copies of brand name drugs.

21 Mar 2005

Are sources of affordable generic medicines drying up?

India should ensure global access to medicines when implementing its patent law.

16 Mar 2005

Wyeth responds to patent lawsuit ruling

Wyeth responded to the ruling today by the U.S. Court of Appeals for the Federal Circuit in the case of Israel Bio-Engineering Project v. Amgen, Inc.

16 Mar 2005

UK leads race to produce world’s first clinical grade stem cells

The University of Sheffield has received a £2.6m grant to create some of the world’s first embryonic stem cell lines that can be used for medicinal purposes.

16 Mar 2005

Drug-resistant bacteria on uncooked poultry products varies by commercial brand

The presence of drug-resistant, pathogenic bacteria on uncooked poultry products varies by commercial brand and is likely related to antibiotic use in production, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

16 Mar 2005

ID Biomedical pursues accelerated approval of influenza vaccine

ID Biomedical Corporation announced today that it has been advised by the United States Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) that the Company's injectable influenza vaccine is eligible for accelerated approval and priority review mechanisms, allowing possible licensure of the vaccine in time to manufacture product for the 2006/07 season.

15 Mar 2005

New flu vaccine for kids hits the market

A new pediatric influenza vaccine that contains no preservatives - the only influenza vaccine approved for use in children 6 to 35 months of age - has been produced by the sanofi-aventis Group, in time for the 2005-2006 influenza season.

10 Mar 2005

U.S Marshals action affects Glaxo share price

Early this month, U.S. marshals seized batches of Paxil CR and Avandamet at manufacturing and distribution sites in Puerto Rico and Knoxville, Tennessee.

8 Mar 2005

New system for growing human embryonic stem cells could make therapies utilising the cells safer for patients

A new system for growing human embryonic stem cells could make therapies utilising the cells safer for patients, concludes a study published online by The Lancet (Tuesday, March 8, 2005).

8 Mar 2005

UK will vote against the declaration on human cloning

The UN declaration is non-binding and has no legal status, but it calls on countries to prohibit all forms of human cloning. This is totally unacceptable to the UK government which strongly supports stem cell research, including embryonic stem cell research which involves the use of cloning technology.

8 Mar 2005

WHO says countries should stockpile H5N1 vaccine

The World Health Organization is about to advise countries to stockpile the influenza vaccine strain known as H5N1, responsible for the deadly birdflu outbreak in Southeast Asia.

7 Mar 2005

Batches of the drugs Paxil and Avandamet seized by federal officials

Batches of the drugs Paxil CR and Avandamet United States, were seized by marshals at manufacturing and distribution plants in Tennessee and Puerto Rico after federal officials said the manufacturer failed to correct violations of production safety standards.

5 Mar 2005

Key players within the European medical device market

The European medical device industry is highly competitive, where new and smaller participants find it extremely challenging to make a significant impact. It is also a dynamic industry with continued scope for expansion, given the ageing population and consequent rise in the number of people suffering from cardiovascular diseases, cancers, musculoskeletal disorders and diabetes.

1 Mar 2005

Oak Ridge technology used to understand semiconductor defects helps people at risk of becoming blind

Millions of people at risk of becoming blind could one day be helped by an Oak Ridge National Laboratory technology originally intended to understand semiconductor defects.

10 Feb 2005

Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications

The Institute of Bioengineering and Nanotechnology (IBN) has developed a novel method to simultaneously control the size and morphology of nanoparticles, which can be used in pharmaceutical synthesis and novel biomedical applications.

8 Feb 2005

Monoclonal antibody therapeutics to fill vacuum left by ineffective conventional therapies

Currently, the limited efficacy of conventional therapies, especially in the case of several oncology and autoimmune and inflammatory disorders (AIID), is creating the need for safe and effective treatment alternatives.

25 Jan 2005

Small is beautiful in the medical world

Small is beautiful in the medical world. And being able to give European industry the edge in a nearly €200 billion worldwide biomedical market is what drives a consortium of EU-backed partners to make and market smaller, cheaper and better biomedical devices and innovative new applications.

19 Jan 2005

ID Biomedical begins development of pandemic influenza vaccine

ID Biomedical announced today that it has begun development of an experimental ("mock") vaccine against a strain of the influenza virus, H5N1, that experts believe could cause a deadly worldwide epidemic (pandemic) of influenza.

19 Jan 2005

New filter promises clean water for millions

A handful of clay, yesterday’s coffee grounds and some cow manure are the simple ingredients that could bring clean drinking water to developing countries around the globe.

19 Jan 2005

FDA knocks back anticancer drug Marqibo

Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.

19 Jan 2005